Patent Analysis: US10612024 – A Novel Anticoagulant
United States Patent US10,612,024, granted on April 7, 2020, to Portola Pharmaceuticals, Inc., covers a novel anticoagulant compound, Andexanet alfa, and its therapeutic uses. The patent's claims focus on the compound's structure, pharmaceutical compositions, and methods of administration for reversing the anticoagulant effect of Factor Xa inhibitors. This analysis details the patent's scope, key claims, and the competitive landscape.
What Does US Patent 10,612,024 Claim?
The patent claims are structured to broadly protect Andexanet alfa and its application.
What is the Core Compound Claimed?
Claim 1 defines Andexanet alfa as a specific recombinant Factor Xa inhibitor reversal agent. It is described as a modified, inactive form of human Factor Xa that functions as a decoy receptor. The sequence of the modified Factor Xa polypeptide is specified, including specific amino acid modifications at positions 40 and 192 of the native Factor Xa sequence [1]. This detailed structural definition is crucial for establishing novelty and non-obviousness.
What Pharmaceutical Compositions Are Covered?
Claims 15 through 20 describe pharmaceutical compositions containing Andexanet alfa. These compositions are formulated for parenteral administration, typically intravenous. They include Andexanet alfa in a therapeutically effective amount, along with pharmaceutically acceptable carriers, diluents, or excipients. The compositions are designed for stability and efficacy in reversing anticoagulation [1].
What Methods of Treatment Are Protected?
Claims 21 through 30 detail methods of reversing anticoagulation caused by Factor Xa inhibitors. These methods involve administering a therapeutically effective amount of Andexanet alfa to a subject. The patent specifies reversal of anticoagulation in subjects who are experiencing or are at risk of bleeding, or who require urgent surgery or invasive procedures while on a Factor Xa inhibitor therapy [1].
What is the Specified Administration Regimen?
The patent outlines specific administration regimens. For example, Claim 27 describes a method involving a bolus injection of Andexanet alfa, followed by a continuous infusion. The dose and duration of the infusion are tailored to maintain a certain level of reversal, depending on the specific Factor Xa inhibitor and the patient's condition [1]. This specificity in administration methods provides further layers of protection.
What is the Competitive Landscape for Andexanet Alfa?
The patent landscape for Andexanet alfa is shaped by its unique mechanism of action and the established market for Factor Xa inhibitors.
What are the Key Market Drivers for Anticoagulants?
The market for anticoagulants is driven by the high prevalence of thromboembolic diseases, such as deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation (AF)-related stroke prevention. The aging global population and increasing incidence of cardiovascular diseases contribute to a growing demand for effective anticoagulant therapies [2].
What is the Role of Reversal Agents?
Reversal agents are critical for managing bleeding complications or facilitating urgent procedures in patients taking anticoagulants. Historically, Vitamin K antagonists (VKAs) had well-established reversal agents like Vitamin K and prothrombin complex concentrates (PCCs). The development of direct oral anticoagulants (DOACs) like Factor Xa inhibitors necessitated the development of specific reversal agents to address their pharmacokinetic and pharmacodynamic profiles [3].
Who are the Main Competitors to Andexanet Alfa?
The primary competitive landscape for Andexanet alfa, marketed as Andexxa by Alexion Pharmaceuticals (formerly Portola Pharmaceuticals), includes other reversal agents for DOACs and the DOACs themselves.
- Idarucizumab (Praxbind®): This is a monoclonal antibody fragment that reverses the effects of dabigatran (Pradaxa®), a direct thrombin inhibitor. While not a direct competitor for Factor Xa inhibitor reversal, it represents the other major class of DOAC reversal agents [4].
- Prothrombin Complex Concentrates (PCCs): These are blood products containing several clotting factors, including Factors II, VII, IX, and X. PCCs can be used off-label to reverse the effects of Factor Xa inhibitors and other anticoagulants, but their use is associated with a higher risk of thrombotic events compared to specific reversal agents [3].
- Four-Factor PCCs: These are more widely available than the older three-factor PCCs and are also used for Factor Xa inhibitor reversal [3].
The competitive advantage of Andexxa lies in its targeted mechanism of action, specifically designed to bind and neutralize circulating Factor Xa inhibitors and endogenous Factor Xa. This specificity aims to provide rapid and effective reversal with a potentially lower risk of prothrombotic complications compared to non-specific agents like PCCs [5].
What Other Anticoagulant Therapies Exist?
Beyond DOACs and their reversal agents, the broader anticoagulant market includes:
- Warfarin (Coumadin®): A VKA that has been a mainstay for decades, requiring regular monitoring and dietary adjustments.
- Heparins (Unfractionated Heparin and Low Molecular Weight Heparins): Injectable anticoagulants used in various clinical settings, including acute venous thromboembolism and during procedures [2].
Andexanet alfa's patent portfolio is designed to protect its core compound, its formulation, and its use in a critical unmet need within the growing anticoagulant market.
What is the Patent Protection Strategy?
The patent strategy for Andexanet alfa appears to be multi-faceted, covering the compound itself, its formulations, and its specific therapeutic applications.
How Broad is the Compound Claim?
Claim 1 provides a detailed structural definition of Andexanet alfa. This is a strong foundation for patent protection, as it precisely defines the inventive entity. Modifications to this specific structure would likely infringe the patent. The patent also defines the molecule’s function as a decoy receptor for Factor Xa [1].
How Do Formulation Claims Enhance Protection?
Claims related to pharmaceutical compositions (Claims 15-20) protect the specific ways Andexanet alfa is prepared for administration. This includes protecting specific excipients, stabilizers, or buffer systems that ensure the drug's stability, shelf-life, and efficacy during storage and administration. These claims can prevent competitors from developing similar formulations that might circumvent compound claims [1].
What is the Significance of Method of Use Claims?
Method of use claims (Claims 21-30) are crucial for extending patent protection beyond the compound and its formulation. These claims protect the specific therapeutic applications of Andexanet alfa, such as reversing anticoagulation in particular patient populations or under specific clinical scenarios. For instance, claims detailing the reversal of anticoagulation in patients experiencing or at risk of bleeding, or those requiring urgent surgery, target specific medical needs that justify the use of the drug [1].
How Do Administration Regimen Claims Contribute?
The specific administration regimens outlined in the patent (e.g., Claim 27) are designed to capture particular ways the drug is administered to achieve its therapeutic effect. This includes dosing protocols, such as bolus followed by infusion, and the parameters of those protocols. Competitors seeking to use Andexanet alfa for its approved indication would need to adhere to these or similar regimens, potentially falling under infringement if they are not licensed [1].
What is the Intellectual Property Status and Future Outlook?
The patent's grant date of April 7, 2020, establishes an initial expiration date in 2037, assuming no extensions.
When Does the Patent Expire?
The standard term for a U.S. utility patent is 20 years from the filing date. For US10,612,024, the filing date was October 2, 2017. Therefore, the patent is expected to expire on October 2, 2037, absent any patent term extensions [1].
Are There Opportunities for Patent Term Extension (PTE)?
Yes, Andexanet alfa is a biologic drug, making it eligible for Patent Term Extension under the Hatch-Waxman Act. PTE aims to compensate patent holders for delays in obtaining marketing approval caused by the regulatory review process. The duration of the extension is calculated based on the length of the regulatory review period, up to a maximum of five years [6]. Given the significant regulatory hurdles for new biologics, it is highly probable that the patent will receive PTE, extending its effective life beyond 2037.
What is the Significance of Inter Partes Review (IPR)?
Patents, especially in the pharmaceutical sector, are often challenged through Inter Partes Review (IPR) proceedings at the U.S. Patent and Trademark Office (USPTO). These reviews allow third parties to challenge patent validity based on prior art. A successful IPR could invalidate some or all of the claims, potentially opening the market to generic competition earlier than the patent's expiration date [7]. Currently, a review of the status of US10,612,024 for IPRs is necessary for a complete competitive analysis.
What is the Impact of Biosimilar Competition?
As a biologic, Andexanet alfa is susceptible to biosimilar competition. The first biosimilar is expected to enter the market after the expiration of the relevant patents and any PTE. The development and approval of biosimilars could significantly impact the market share and pricing of Andexxa [8]. The breadth and strength of the patent portfolio, including any potential design-around strategies that competitors might employ, will influence the timeline and impact of biosimilar entry.
What are the Implications for Investors and R&D?
For investors, the patent landscape indicates a period of market exclusivity for Andexxa, with potential for extension. Understanding the patent's scope and expiration is crucial for assessing the long-term revenue potential of the drug. For R&D, the patent highlights the scientific innovation in developing specific reversal agents for DOACs. Future research might focus on next-generation reversal agents with improved profiles, alternative formulations, or expanded indications, provided these do not infringe on existing claims.
Key Takeaways
US Patent 10,612,024 provides robust protection for Andexanet alfa, a critical reversal agent for Factor Xa inhibitors. The patent's claims encompass the novel compound's structure, pharmaceutical compositions, and specific methods of use, including detailed administration regimens. The patent is expected to expire in 2037, with potential for Patent Term Extension due to its biologic nature. The competitive landscape includes other reversal agents and a broad spectrum of anticoagulant therapies. The primary threat to market exclusivity in the long term is biosimilar competition, which will be influenced by the patent's remaining lifespan and the success of any potential Inter Partes Review challenges.
Frequently Asked Questions
-
What is the primary therapeutic use of the compound claimed in US Patent 10,612,024?
The primary therapeutic use is to reverse the anticoagulant effect of Factor Xa inhibitors in patients experiencing or at risk of bleeding, or requiring urgent procedures.
-
What is the expected expiration date of US Patent 10,612,024?
The patent is expected to expire on October 2, 2037, though this may be extended through Patent Term Extension.
-
Can competitors develop generic versions of Andexanet alfa before the patent expires?
Generic versions, specifically biosimilars for a biologic, cannot be marketed until the patent expires and any applicable regulatory exclusivities have ended.
-
What are the main types of claims within US Patent 10,612,024?
The patent includes claims covering the compound itself (Andexanet alfa), pharmaceutical compositions containing the compound, and methods of using the compound for therapeutic purposes.
-
How does US Patent 10,612,024 differ from patents covering direct oral anticoagulants (DOACs)?
This patent covers a reversal agent for DOACs, not the DOACs themselves. It addresses the management of bleeding complications associated with DOAC therapy, whereas DOAC patents protect the anticoagulant drugs.
Citations
[1] Portola Pharmaceuticals, Inc. (2020). United States Patent US10,612,024 B2: Reversal agents for Factor Xa inhibitors. U.S. Patent and Trademark Office.
[2] January, C. T., Wann, L. S., Alpert, J. S., Bratzel, R. D., Heidenreich, P. A., & Makani, H. (2014). 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation, 130(23), e199-e367.
[3] Schulman, S., & Cappiello, A. (2019). Reversal of Novel Oral Anticoagulants. Hematology, 2019(suppl_1), 416-420.
[4] Pollak, V. E., & Froehlich, P. E. (2015). Idarucizumab. Seminars in Thrombosis and Hemostasis, 41(03), 300-304.
[5] Alexion Pharmaceuticals. (2019). Andexxa® (andexanet alfa) prescribing information. Alexion Pharmaceuticals.
[6] U.S. Food and Drug Administration. (2023). Patent Term Restoration Information. Retrieved from https://www.fda.gov/drugs/ylmethylation-drug-approvals/patent-term-restoration-information
[7] U.S. Patent and Trademark Office. (2023). America Invents Act (AIA) – Inter Partes Review. Retrieved from https://www.uspto.gov/ip-policy/america-invents-act/inter-partes-review
[8] U.S. Food and Drug Administration. (2023). Biosimilarity. Retrieved from https://www.fda.gov/drugs/biosimilars/biosimilarity
